Asthma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Inhaled Corticosteroids (ICS), Leukotriene Modifiers, Immunomodulators, Combination Drugs, Others), By Mode of Administration (Inhalers, Nebulizers, Oral Medications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Asthma Treatment Market was valued at USD 27.84 Billion in 2024 and is expected to reach USD 36.47 Billion by 2030 with a CAGR of 4.58%. This can be ascribed to the increasing prevalence of asthma, growing R&D activities and increasing investment in healthcare infrastructure. Asthma is one of the major public health problem in many countries, particularly in the United States. The high burden of the disease has created a strong demand for effective Asthma Treatment. This has led to significant investment in the development of medications that can prevent Asthma Infection or reduce its severity. The World Health Organization (WHO) estimates that asthma affects around 235 million people worldwide and is responsible for approximately 383,000 deaths annually.

Technological advancements in drug delivery devices, particularly in inhalers and nebulizers, are also shaping the market landscape. Modern inhalers with smart technology capabilities allow for better tracking and management of medication, which is vital for patients with chronic asthma. Furthermore, the development of biologics has opened new doors for treatment, offering patients targeted options that address the underlying causes of asthma. These treatments, such as monoclonal antibodies, have shown effectiveness in controlling severe asthma, thus reducing hospital visits and improving the quality of life. These innovations are expected to propel the market further during the forecast period.

Despite the positive growth outlook, the Global Asthma Treatment Market faces several challenges. One of the primary issues is the high cost of newer biologic treatments, which can limit access for many patients, particularly in low-income regions. Insurance coverage and reimbursement policies also vary, further hindering access to optimal therapies. There is also a need for better adherence to prescribed treatments, as many patients fail to consistently follow asthma management plans, leading to more frequent flare-ups. Regulatory hurdles in some regions, coupled with a fragmented market, pose additional barriers to the widespread availability of new treatments. These factors need to be addressed to ensure continued growth in the market.

Key Market Drivers

Increasing Investment in Research and Development

Pharmaceutical companies are investing heavily in research and development to develop new and innovative asthma treatments. Asthma is a complex disease that requires ongoing management and treatment, and there is a need for new and improved treatments to address unmet medical needs. The National Institutes of Health (NIH) in the United States provides over USD 100 million in funding for asthma research each year, supporting research into new treatments, disease mechanisms, and prevention strategies. It can help to identify new drug targets and treatment options for asthma. This can include the development of novel drugs, biologics, or combination therapies that may provide more effective and targeted treatment options for people with asthma.

Investment in R&D can help to improve the understanding of the underlying mechanisms of asthma and identify new biomarkers for diagnosis and monitoring. This can enable more personalized treatment approaches, which may lead to better outcomes and reduced healthcare costs. Investment in R&D can help to improve asthma management and education, leading to better self-management of the disease and reduced healthcare utilization. It can include the development of new devices and technologies for monitoring and managing asthma symptoms, as well as education programs for healthcare providers and patients.

Increasing Prevalence of Asthma

The growing prevalence of asthma is one of the key drivers of the global asthma treatment market. Asthma is a chronic respiratory condition that is caused by a combination of genetic and environmental factors, which is transmitted to humans through genetics, environmental factors, respiratory infection, obesity, and stress. Global Asthma Report 2018 predicts that asthma will continue to be a significant global health concern, with an increasing burden in low- and middle-income countries. The report notes that without significant improvements in prevention, diagnosis, and treatment, the number of asthma-related deaths may increase by 20% by 2030. The growing prevalence of asthma has led to increased public awareness of the condition. This has helped to reduce stigma around the condition and promote better understanding of the need for effective treatment and management. According to Global Asthma Report 2018, an estimated 339 million people worldwide were affected by asthma in 2016.

 As the prevalence of asthma increases, there is a greater need for healthcare infrastructure to support the diagnosis and treatment of the condition. This can lead to increased investment in healthcare systems, including the development of new clinics, hospitals, and other healthcare facilities. The World Health Organization (WHO) reports that there has been an increase in public awareness about asthma globally in recent years, which has helped to reduce stigma around the condition and promote better understanding of the need for effective treatment and management.

The growing prevalence of asthma drives research and development in the field of asthma treatment. As more people are diagnosed with asthma, there is a greater need for new and more effective treatments to manage the condition.

Advancements in Pharmaceutical Treatments

Advancements in pharmaceutical treatments are playing a significant role in driving the Global Asthma Treatment Market. The evolution of new and improved medications, including biologics, inhalers, and oral therapies, has transformed asthma management, offering patients more effective and targeted options. The development of biologic therapies, such as monoclonal antibodies, has revolutionized the treatment of severe asthma by targeting specific immune pathways that drive inflammation. These therapies have proven especially beneficial for patients with moderate to severe asthma who do not respond well to conventional treatments. By targeting the root causes of inflammation, biologics help reduce asthma exacerbations, improve lung function, and ultimately enhance patients’ quality of life.

The emergence of inhaled therapies, such as combination inhalers that combine corticosteroids and long-acting beta-agonists (LABAs), has also contributed significantly to the market’s growth. These combination products offer better adherence and more effective symptom control compared to separate inhalers. By simplifying treatment regimens, combination inhalers have become a preferred option for patients, particularly those with moderate asthma who require ongoing maintenance therapy.

Innovations in oral medications, such as leukotriene receptor antagonists (LTRAs), have further expanded treatment options for patients. These medications help control asthma symptoms by inhibiting the actions of leukotrienes, inflammatory molecules involved in the asthma response. As new medications with improved efficacy, safety profiles, and fewer side effects continue to emerge, the range of treatment options for asthma patients expands, offering more personalized care. The ongoing development of these advanced pharmaceutical treatments is expected to continue driving the growth of the asthma treatment market, meeting the increasing demand for more effective and convenient asthma management solutions.

Download Free Sample Report

Key Market Challenges

High Cost of Advanced Therapies

One of the significant challenges facing the Global Asthma Treatment Market is the high cost associated with advanced therapies, particularly biologic treatments. These therapies, while highly effective in managing severe asthma, come with a substantial price tag, which can limit accessibility for many patients. Biologic drugs, such as monoclonal antibodies, are often priced significantly higher than conventional asthma medications, with costs ranging from several thousand to tens of thousands of dollars per year per patient. This high cost can be a barrier for patients, especially in low- and middle-income regions, where healthcare coverage and insurance schemes may not fully support such treatments.

The high cost of advanced therapies also presents challenges for healthcare systems, which must balance the need for innovative treatments with budget constraints. This issue becomes more pronounced as the number of asthma patients who require these expensive treatments grows, increasing the financial burden on public and private health systems. For many patients, the out-of-pocket expenses for biologic therapies can be prohibitively expensive, leading to treatment delays, non-adherence, or, in some cases, the inability to access necessary medications.

Pharmaceutical companies, while driving innovation in asthma treatment, are often under pressure to reduce costs and make these therapies more accessible. However, this challenge is complicated by the high costs of research, development, and regulatory approval required for biologic therapies. As the demand for such treatments increases, finding ways to reduce costs without compromising the effectiveness of the therapies will be crucial for ensuring that these advanced asthma treatments remain accessible to all patients, regardless of their financial situation.

Side Effects and Safety Concerns

Side effects and safety concerns are significant challenges in the Global Asthma Treatment Market, particularly with the increasing use of new therapies. While asthma treatments, including inhalers, biologics, and oral medications, are essential in managing the disease, they often come with a range of side effects that can compromise patient adherence and quality of life.

Inhaled corticosteroids, widely used for managing asthma, are effective but may cause adverse effects such as oral thrush, hoarseness, and throat irritation. Long-term use of these drugs can also lead to more severe complications like osteoporosis and growth suppression in children. For patients on combination therapies that include corticosteroids and long-acting beta-agonists (LABAs), there is an increased risk of cardiovascular events, such as heart palpitations and hypertension, especially in older populations. These concerns can deter patients from adhering to prescribed regimens or lead to the discontinuation of effective treatments.

Biologic therapies, though revolutionary, are also not without risks. These treatments target specific immune system pathways and can result in serious side effects like allergic reactions, infections, and even malignancies in some cases. The use of biologics in asthma treatment is typically reserved for patients with severe disease, who may be at higher risk for these adverse effects. However, the cost of biologic drugs and the monitoring required for potential side effects raise barriers to their widespread adoption.

The safety concerns surrounding these treatments are further compounded by the complexity of asthma itself, as its triggers and manifestations vary greatly among individuals. This variation makes it challenging to predict which treatments will be most effective and safe for each patient, complicating decision-making processes for both patients and healthcare providers. As a result, addressing side effects and safety concerns remains a critical issue in the asthma treatment market.

Key Market Trends

Integration of Digital Health Technologies

The integration of digital health technologies is becoming a prominent trend in the Global Asthma Treatment Market, significantly transforming how asthma is managed and treated. Mobile applications, wearable devices, and smart inhalers are revolutionizing the approach to asthma care, enabling patients to actively participate in managing their condition. Smart inhalers equipped with sensors are designed to track inhaler use, sending real-time data to both patients and healthcare providers. This not only ensures timely medication adherence but also offers insights into potential triggers and symptom patterns, enhancing treatment outcomes.

Mobile applications specifically developed for asthma management enable patients to log their symptoms, monitor medication usage, and track environmental factors that might trigger asthma attacks. These apps empower users to make informed decisions about their treatment and avoid potential triggers. Through regular updates, patients can share detailed information about their condition, which can be reviewed by healthcare providers, fostering a collaborative approach to care. This real-time monitoring also facilitates the timely adjustment of treatment plans, reducing hospital visits and preventing asthma exacerbations.

The use of telemedicine is another vital aspect of digital health integration. Virtual consultations with healthcare professionals allow patients to access expert advice without the need for frequent in-person visits. This is particularly beneficial for patients living in remote or underserved areas. The combination of digital tools and telemedicine increases accessibility to asthma care, improves medication adherence, and helps prevent complications. These technologies collectively contribute to better asthma control, enhanced patient engagement, and more efficient healthcare delivery, positioning digital health solutions as a crucial component of the future of asthma treatment.

Personalized Medicine and Genetic Insights

Personalized medicine and genetic insights are rapidly shaping the future of the Global Asthma Treatment Market by offering more precise, tailored approaches to managing the condition. Advances in genomics and molecular biology have enabled the identification of specific genetic factors that contribute to asthma susceptibility, severity, and response to treatment. This level of understanding allows healthcare providers to customize treatments based on an individual’s unique genetic makeup, ensuring more effective management of asthma with fewer side effects.

A key driver of this trend is the increasing recognition that asthma is not a one-size-fits-all disease. It encompasses various subtypes, each with its own underlying molecular mechanisms. Genetic profiling, along with biomarkers, enables the classification of asthma into specific phenotypes, such as eosinophilic asthma, which often requires different treatment protocols compared to other types. For instance, biologic therapies like monoclonal antibodies (e.g., Dupixent and Fasenra) are particularly effective for patients with eosinophilic asthma, as these therapies target the specific pathways involved in inflammation.

The growing focus on personalized medicine also extends to the development of pharmacogenomics, where drug efficacy is optimized based on the genetic makeup of patients. This approach helps determine the most appropriate treatment and dosage for each individual, minimizing the trial-and-error process that has traditionally been part of asthma management. Genetic insights also aid in early diagnosis, allowing healthcare providers to intervene earlier in a patient’s asthma progression, potentially preventing more severe symptoms and complications.

As genetic testing becomes more accessible and affordable, personalized treatments are expected to become more widespread. This trend is anticipated to drive the demand for tailored asthma therapies, contributing to improved patient outcomes and a shift away from generalized treatment approaches.

Segmental Insights

Drug Class Insights

Based on the Drug Class, Combination Drugs emerged as the dominant segment in the Global Asthma Treatment Market in 2024. This is due to their enhanced ability to manage multiple symptoms of asthma with a single formulation. Combination drugs, typically containing an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA), offer both anti-inflammatory and bronchodilatory effects, making them highly effective in controlling moderate to severe asthma cases. Their convenience in dosing and improved patient compliance compared to using separate medications contributed significantly to their widespread adoption among healthcare providers and patients. Healthcare professionals increasingly prefer combination therapies as they simplify treatment regimens and reduce the risk of patient non-adherence, which is crucial for achieving better long-term asthma control. Pharmaceutical companies are also investing heavily in developing advanced combination inhalers with smart inhalation tracking technologies, further boosting this segment’s dominance. Regulatory approvals for newer combination therapies have expanded their availability across various markets, supporting strong growth.

Mode of Administration Insights

Based on the Mode of Administration, Inhalers emerged as the dominant segment in the Global Asthma Treatment Market in 2024. This dominance is driven by their efficiency, convenience, and ability to deliver medication directly to the lungs. Inhalers provide rapid symptom relief and are highly preferred for both maintenance therapy and emergency use in asthma management. Their portable design allows patients to carry them easily and use them whenever symptoms arise, significantly enhancing treatment adherence and improving quality of life for individuals with asthma. The wide variety of inhalers available, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs), has enabled healthcare providers to tailor treatment options to individual patient needs. Technological advancements, such as smart inhalers equipped with sensors to monitor medication usage and ensure adherence, have further strengthened the appeal of this mode of administration.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Asthma Treatment Market in 2024. This is supported by its advanced healthcare infrastructure, high prevalence of asthma, and strong focus on innovative treatment options. The region benefits from a well-established network of healthcare providers, specialized respiratory care centers, and widespread patient access to cutting-edge therapies. Favorable reimbursement policies and government initiatives aimed at improving asthma management have significantly enhanced patient access to quality care, boosting the demand for asthma treatments across the United States and Canada. The presence of major pharmaceutical companies investing heavily in research and development for new asthma medications and biologics has further strengthened the region’s leadership in the market. Increasing awareness about early diagnosis, patient education programs, and adoption of personalized medicine approaches have also contributed to better asthma control and a rising demand for specialized treatments.

Asia-Pacific emerged as the fastest growing region in the Global Asthma Treatment Market during the forecast period. This is driven by a significant rise in asthma prevalence across densely populated countries such as China, India, and Indonesia. Rapid urbanization, worsening air pollution levels, and increased exposure to allergens have contributed to the growing patient base requiring asthma management solutions. Governments across the region have been taking proactive steps to improve respiratory healthcare infrastructure by launching national health programs and funding awareness campaigns. The rising disposable income among middle-class populations has led to greater healthcare spending, enabling patients to access advanced treatments and branded medications. In addition, international pharmaceutical companies are increasingly targeting the Asia-Pacific region through partnerships, local manufacturing, and tailored product launches, further accelerating market growth.

Recent Developments

• In February 2025, Enveda, a biotechnology company leveraging AI for drug discovery, announced the testing of its lead asset, ENV-294, for a second indication: asthma. Originally developed for atopic dermatitis, ENV-294 offers a novel approach to treating respiratory inflammatory conditions. To support this initiative, Enveda has established an advisory board of leading asthma research and treatment experts.
• In January 2025, Kinaset Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for frevecitinib (KN-002), an inhaled dry powder treatment for asthma patients inadequately controlled by standard inhaled therapies. The company plans to initiate a Phase 2b dose-ranging trial by mid-2025.
• In October 2024, AstraZeneca announced positive results from the Phase IIIb BATURA trial for its product, AIRSUPRA (albuterol/budesonide). The trial demonstrated that AIRSUPRA significantly reduced the risk of severe asthma exacerbations when used as an as-needed rescue medication compared to albuterol alone. The study included patients with intermittent or mild persistent asthma, including those on short-acting beta2-agonists (SABA), low-dose inhaled corticosteroids (ICS), or leukotriene receptor antagonists (LTRA) as maintenance therapy.
• In April 2024, AstraZeneca’s FASENRA (benralizumab) received US FDA approval as an add-on maintenance treatment for children aged 6 to 11 with severe eosinophilic asthma. Previously approved in 2017 for patients aged 12 and older, this new indication is backed by the Phase III TATE study, which confirmed consistent pharmacokinetics, pharmacodynamics, safety, and tolerability in younger patients. The recommended dosage is 30 mg for those weighing 35 kg or more, and a newly introduced 10 mg dose for children under 35 kg. FASENRA is administered via subcutaneous injection every 4 weeks for the first three doses, then every 8 weeks.
• In January 2024, AstraZeneca announced that AIRSUPRA (albuterol/budesonide) is now commercially available in the U.S. by prescription. Approved by the FDA in January 2023, AIRSUPRA is indicated for the as-needed treatment or prevention of asthma symptoms and to prevent sudden severe asthma attacks in adults aged 18 and older. AIRSUPRA combines a short-acting beta2-agonist (SABA) to relax airway smooth muscles and an inhaled corticosteroid (ICS) to reduce lung inflammation.

Key Market Players

• GlaxoSmithKline, Plc
• AstraZeneca Plc
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim Gmbh
• Merck & Co. Inc.
• Novartis AG
• Sanofi SA
• Roche Holding AG
• Regeneron Pharmaceutical Inc.
• Pfizer Inc.

Report Scope:

In this report, the Global Asthma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Asthma Treatment Market, By Drug Class:

o   Short-Acting Beta-Agonists (SABA)

o   Long-Acting Beta-Agonists (LABA)

o   Inhaled Corticosteroids (ICS)

o   Leukotriene Modifiers

o   Immunomodulators

o   Combination Drugs

o   Others

• Asthma Treatment Market, By Mode of Administration:

o   Inhalers

o   Nebulizers

o   Oral Medications

• Asthma Treatment Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

o   Others

• Asthma Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Asthma Treatment Market.

Available Customizations:

Global Asthma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Asthma Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com